Specific laminin binding to interleukins enhances diabetic wound healing
This study reveals that laminins and fibronectin bind interleukins through distinct, heparin-independent sites to regulate immune responses, demonstrating that a laminin-functionalized hydrogel enhances diabetic wound healing by potentiating IL-10 signaling while also introducing a novel AI-driven chemical labeling method to overcome antibody interference in mapping these interactions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body is a landscape of tissues, each held together and guided by a complex, invisible scaffolding known as the extracellular matrix. Think of this matrix not as a static wall, but as a dynamic, living library where the body stores its most important chemical messages. For decades, scientists understood that this library held growth factors—molecules that tell cells to multiply, move, or build new structures. They knew the shelves of this library, made of proteins like laminin, had specific spots where these growth factors could park, waiting to be released when the body needed them. However, a different class of messengers, called interleukins, which act as the immune system's radio signals to coordinate inflammation and healing, were thought to operate outside this system. The prevailing view was that these immune signals did not bind to the matrix in the same way, leaving a gap in our understanding of how the body's structural framework might also help regulate its immune response. This distinction matters deeply when the body is injured, particularly in conditions like diabetes where wounds fail to heal because the immune system gets stuck in a state of chronic inflammation, preventing the repair process from ever truly beginning.
A team of researchers has now discovered that this separation between structural support and immune signaling is an illusion. They found that laminin, a major structural protein, also acts as a reservoir for interleukins, holding them in place just as it does for growth factors. This discovery is significant because it reveals a new way the body might naturally control inflammation. The scientists showed that these immune molecules bind to laminin at specific locations that are entirely different from where growth factors attach. Unlike growth factors, which often rely on a sugar-based molecule called heparin to stick to the protein, interleukins bind directly to the laminin structure itself, using their own unique docking sites. This means the body has a dedicated, independent system for managing immune signals within its structural framework, one that does not depend on the same chemical bridges used for growth.
To find these hidden docking sites, the researchers had to overcome a technical hurdle. When they tried to use standard antibodies to detect where interleukins were binding, the antibodies physically blocked the connection, making the sites invisible. To solve this, they developed a new method that replaced the antibodies with a chemical tag, allowing them to see the binding without interference. They then combined this experimental approach with artificial intelligence to predict exactly where on the massive laminin protein the interleukins would attach. The AI models suggested specific spots, and the team validated these predictions in the lab. They confirmed that interleukins bind to various parts of the laminin molecule, including sections that had never been known to interact with immune signals before. Crucially, they proved that these interactions were not blocked by heparin, confirming that the body uses a fundamentally different mechanism to store and release these immune signals compared to growth factors.
The study then focused on one specific interleukin, IL-10, which is known for its ability to calm inflammation and promote healing. The researchers wanted to see if the laminin matrix could do more than just hold this molecule; they wanted to know if the combination could actually change how immune cells behave. They grew immune cells, called macrophages, on a surface coated with a specific type of laminin known as laminin-111. They found that when these cells encountered IL-10 in the presence of this specific laminin, they shifted into a highly effective healing mode. This shift was driven by a conversation between the laminin and a receptor on the cell surface, which amplified the signal from the IL-10. The result was a cell that was better at clearing debris and reducing inflammation, a state that is essential for moving a wound from a stuck, inflamed phase into a phase of active repair.
To test if this mechanism could work in a living organism, the team created a new type of wound dressing. They built a soft, gel-like material and embedded the specific laminin protein into it, loading the gel with IL-10. They applied this dressing to full-thickness wounds on mice with type 2 diabetes, a condition where wounds typically fail to heal due to persistent inflammation. The results were striking. The wounds treated with the laminin-based gel healed significantly faster and more completely than those treated with standard commercial dressings or gels without the laminin. The treated wounds showed a better organization of new tissue, with collagen fibers arranged in a pattern that resembled healthy skin rather than a scar. Furthermore, the treatment reduced the presence of neutrophils, a type of white blood cell that can cause damage when it stays too long in a wound, and increased the number of the helpful, healing-focused immune cells.
The researchers also explored whether adding a second molecule, VEGF-A165, which helps grow new blood vessels, would improve the results further. While the addition of this growth factor did speed up the very early stages of healing by about a day, the primary driver of the successful outcome remained the combination of the laminin protein and the IL-10. The study suggests that the laminin protein does not just act as a passive carrier; it actively enhances the signal from the immune molecule, making the healing process more efficient. This finding points to a broader principle: the body's structural proteins are not just scaffolding but active participants in immune regulation. By understanding how these proteins naturally hold and amplify immune signals, scientists may be able to design better treatments for chronic wounds and other conditions where the immune system fails to reset. The work opens a new path for therapies that mimic the body's own natural methods of controlling inflammation and promoting regeneration, offering hope for conditions where current treatments fall short.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.